For the first time in Medicare's 61-year history, Part D will cover GLP-1 medications like Wegovy and Zepbound for weight loss when the obesity indication becomes billable on July 1, 2026. The mechanism that makes this financially viable is the CMS GLP-1 Bridge — an 18-month demonstration that runs July 1, 2026 through December 31, 2027 and caps what qualifying Part D patients pay while CMS studies the costs. CMS had also developed a companion value-based framework called the Balance Model, but on April 21, 2026 it announced the Balance Model would not be implemented in Medicare — it was ultimately adopted only in Medicaid. For Medicare patients, the Bridge is the program that determines what you will actually pay this summer, and whether you qualify for it.
If you are a Part D enrollee with a BMI of 30 or higher, or 27 with a qualifying comorbidity, this is the most important Medicare policy shift of the decade. Here is exactly how the Bridge works, who qualifies, and what you need to do before July.
What Is the CMS Balance Model?
The Balance Model is a value-based payment pilot developed by the Center for Medicare and Medicaid Innovation (CMMI), the experimental arm of CMS created under the Affordable Care Act. Unlike traditional Medicare Part D — which pays a fixed negotiated rate regardless of patient outcomes — the Balance Model ties drug reimbursement directly to clinical performance. Manufacturers get paid more when patients achieve measurable outcomes (weight loss percentages, A1C reductions, cardiovascular events avoided), and less when they do not.
For GLP-1 medications, that means manufacturers like Novo Nordisk and Eli Lilly get paid based on whether enrollees actually lose weight and stay on therapy — not just on how many prescriptions get filled. CMS framed the model as a way to afford category-level coverage for expensive chronic-condition drugs. But on April 21, 2026, CMS announced it would not implement the Balance Model in Medicare. The model launched instead in Medicaid on May 1, 2026, where it is scheduled to run through 2031. Medicare's GLP-1 coverage runs through the Bridge demonstration described below, not the Balance Model.
The Balance Model is legally distinct from the Inflation Reduction Act's Medicare drug price negotiation program, though both policies are pushing toward the same outcome: lower costs for high-spend drugs.
Which GLP-1 Medications Does the Bridge Cover in 2026?
The Bridge is narrow. It applies specifically to GLP-1s prescribed for the obesity indication — not diabetes. That distinction matters.
Wegovy (semaglutide 2.4mg) — Covered under the Bridge for the obesity indication. Novo Nordisk's flagship weight loss injection is the anchor product in the program.
Zepbound (tirzepatide) — Covered under the Bridge for obesity. Eli Lilly's dual GIP/GLP-1 agonist is the second pillar of the program.
Ozempic and Mounjaro — Still covered under traditional Part D for their type 2 diabetes indications. These are not part of the Bridge because their diabetes use was already a covered benefit under the original Part D statute.
Foundayo (orforglipron) — Covered. Eli Lilly's oral GLP-1 pill was FDA-approved on April 1, 2026 and is included in the Bridge's $50/month coverage alongside Wegovy and Zepbound.
The $50/month Bridge Program caps patient out-of-pocket costs for qualifying Part D enrollees. It is an 18-month demonstration that CMS extended to run July 1, 2026 through December 31, 2027.
Medicare GLP-1 Bridge Program 2026: How It Works
The Bridge Program is the heart of Medicare's 2026 GLP-1 coverage. It runs from July 1, 2026 through December 31, 2027, and caps out-of-pocket costs at $50 per month for eligible Part D enrollees filling a qualifying GLP-1 prescription for obesity.
Eligibility requirements:
- Enrollment in a Medicare Part D prescription drug plan (standalone or through Medicare Advantage Part D)
- Body mass index of 30 or higher, OR 27 or higher with at least one weight-related comorbidity
- Qualifying comorbidities include hypertension, obstructive sleep apnea, dyslipidemia, and type 2 diabetes
- Prescribing physician documentation of obesity diagnosis (ICD-10 E66.x) in your medical record
Prior authorization: Yes. Each Part D plan will require a prior auth form signed by your prescriber attesting to BMI, comorbidity status, and that lifestyle modification has been attempted. Plans have been instructed to process these within 72 hours once the benefit goes live.
What happens through 2027: The $50/month cap stays in place for the life of the demonstration, which now runs through December 31, 2027. Note that the $50 copay does not count toward your Part D deductible or your annual out-of-pocket maximum ($2,100 in 2026, rising to $2,400 in 2027). What comes after the Bridge has not been finalized: CMS decided not to bring the Balance Model into Medicare, so the agency will use 2027 cost and outcomes data to decide whether GLP-1 obesity coverage becomes a permanent Part D benefit.
Who Qualifies for Medicare Bridge GLP-1 Coverage?
You qualify if all three of the following apply:
First, you are enrolled in Medicare Part D — either as a standalone drug plan layered on Original Medicare, or as part of a Medicare Advantage plan that includes drug coverage. Dual-eligible beneficiaries (Medicare plus Medicaid) are covered under separate rules that vary by state.
Second, you meet the BMI and comorbidity threshold: BMI 30+, or BMI 27+ with hypertension, sleep apnea, dyslipidemia, type 2 diabetes, or another documented weight-related condition.
Third, you are not in an exclusion category. Current exclusions include gestational obesity, active treatment for certain cancers, medullary thyroid carcinoma history, and multiple endocrine neoplasia syndrome type 2.
To apply, contact your Part D plan directly starting in June 2026. Most plans are building dedicated GLP-1 enrollment portals that will go live 2-4 weeks before the July 1 start date. You will need your prescriber to submit the prior authorization packet on your behalf.
Cost Breakdown: What You'll Actually Pay
Through December 2027 (Bridge Program): $50/month out-of-pocket, period. No deductible reset surprises, no coinsurance tier shifting.
Compared to cash price: Wegovy's list price is approximately $1,350/month. Zepbound runs $1,060/month list. The Bridge program is an 96% discount off list for Wegovy and 95% off for Zepbound.
Savings card interaction: Here is a critical catch. Under CMS rules, manufacturer savings cards cannot stack with Medicare Part D benefits. If you have been using Novo Nordisk's WegovyCare savings card or Eli Lilly's Zepbound savings card, you will need to stop using them once you enter the Bridge Program. This is a longstanding CMS anti-kickback policy, not a new rule.
After 2027: The Bridge runs through December 31, 2027. Because CMS chose not to adopt the Balance Model in Medicare, what follows the Bridge has not yet been finalized — CMS will decide, based on 2027 cost and outcomes data, whether to make GLP-1 obesity coverage a permanent Part D benefit or let it lapse.
Timeline: Key Dates for Medicare GLP-1 Coverage 2026-2027
- June 2026 — Part D plans open GLP-1 prior authorization portals
- July 1, 2026 — Bridge Program goes live, $50/month cap begins
- October 2026 — Medicare Open Enrollment; compare Part D plans for 2027 GLP-1 coverage
- Throughout 2027 — Bridge Program continues; $50/month cap stays in place
- December 31, 2027 — Bridge demonstration ends; CMS reviews cost and outcomes data
- 2028 — CMS decides whether GLP-1 obesity coverage becomes a permanent Part D benefit (not yet finalized)
What To Do Next
If you are on Medicare Part D and think you qualify, the single most valuable thing you can do right now is schedule an appointment with your primary care provider to document your BMI and any qualifying comorbidities in your medical record. That documentation is what your Part D plan will review when processing your prior authorization in June or July.
For a deeper breakdown of Medicare GLP-1 coverage timelines and plan-by-plan details, read our Medicare GLP-1 2026 coverage guide. To compare drug-specific costs, see our Wegovy cost analysis and Zepbound cost analysis. And for the 5 things every eligible American should prepare before July, read our Medicare Bridge Program preparation guide.
The Bridge is not a finished policy — it is a demonstration that CMS will study and then either make permanent or let lapse based on 2027 outcomes data. But for the millions of Medicare enrollees who have been priced out of GLP-1 therapy, July 1 is the day the door finally opens.